X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with J.B.Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs J.B.CHEMICALS - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA J.B.CHEMICALS DISHMAN PHARMA/
J.B.CHEMICALS
 
P/E (TTM) x 25.1 17.1 146.4% View Chart
P/BV x 3.3 2.3 144.3% View Chart
Dividend Yield % 0.7 0.2 397.5%  

Financials

 DISHMAN PHARMA   J.B.CHEMICALS
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
J.B.CHEMICALS
Mar-16
DISHMAN PHARMA/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs374318 117.7%   
Low Rs129200 64.6%   
Sales per share (Unadj.) Rs197.8148.0 133.7%  
Earnings per share (Unadj.) Rs21.219.1 111.1%  
Cash flow per share (Unadj.) Rs34.723.9 145.0%  
Dividends per share (Unadj.) Rs2.000.50 400.0%  
Dividend yield (eoy) %0.80.2 411.4%  
Book value per share (Unadj.) Rs179.9128.9 139.5%  
Shares outstanding (eoy) m80.6984.82 95.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.31.7 72.7%   
Avg P/E ratio x11.913.6 87.5%  
P/CF ratio (eoy) x7.210.8 67.1%  
Price / Book Value ratio x1.42.0 69.7%  
Dividend payout %9.42.6 360.0%   
Avg Mkt Cap Rs m20,30621,951 92.5%   
No. of employees `0000.82.7 30.3%   
Total wages/salary Rs m5,3551,841 290.8%   
Avg. sales/employee Rs Th19,252.74,590.9 419.4%   
Avg. wages/employee Rs Th6,459.5673.4 959.2%   
Avg. net profit/employee Rs Th2,064.1592.1 348.6%   
INCOME DATA
Net Sales Rs m15,96112,551 127.2%  
Other income Rs m265542 49.0%   
Total revenues Rs m16,22613,093 123.9%   
Gross profit Rs m4,1032,055 199.7%  
Depreciation Rs m1,091412 264.5%   
Interest Rs m94496 986.8%   
Profit before tax Rs m2,3342,088 111.8%   
Minority Interest Rs m00 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624469 132.9%   
Profit after tax Rs m1,7111,619 105.7%  
Gross profit margin %25.716.4 157.0%  
Effective tax rate %26.722.5 119.0%   
Net profit margin %10.712.9 83.1%  
BALANCE SHEET DATA
Current assets Rs m11,0187,778 141.7%   
Current liabilities Rs m9,5174,358 218.4%   
Net working cap to sales %9.427.2 34.5%  
Current ratio x1.21.8 64.9%  
Inventory Days Days11055 202.1%  
Debtors Days Days3580 43.5%  
Net fixed assets Rs m16,3045,713 285.4%   
Share capital Rs m161170 95.2%   
"Free" reserves Rs m12,90710,547 122.4%   
Net worth Rs m14,51610,937 132.7%   
Long term debt Rs m4,1890-   
Total assets Rs m29,80515,574 191.4%  
Interest coverage x3.522.8 15.2%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.50.8 66.4%   
Return on assets %8.911.0 80.9%  
Return on equity %11.814.8 79.6%  
Return on capital %17.520.0 87.8%  
Exports to sales %24.848.7 50.9%   
Imports to sales %3.77.1 52.8%   
Exports (fob) Rs m3,9566,115 64.7%   
Imports (cif) Rs m596889 67.1%   
Fx inflow Rs m4,9526,169 80.3%   
Fx outflow Rs m6971,285 54.2%   
Net fx Rs m4,2554,884 87.1%   
CASH FLOW
From Operations Rs m2,7861,397 199.5%  
From Investments Rs m-1,529-320 477.3%  
From Financial Activity Rs m-941-1,196 78.7%  
Net Cashflow Rs m316-102 -309.3%  

Share Holding

Indian Promoters % 61.4 55.4 110.8%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 3.7 3.4 109.1%  
FIIs % 12.7 3.9 325.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 37.0 59.7%  
Shareholders   46,261 30,437 152.0%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   TTK HEALTHCARE  SUVEN LIFE  CIPLA  ELDER PHARMA  VENUS REMEDIES  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS